Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Epidermal Growth ◽

Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer

Current Opinion in Oncology ◽

10.1097/01.cco.0000397417.75245.9c ◽

2011 ◽

Vol 23 ◽

pp. S3-S9 ◽

Cited By ~ 8

Author(s):

Margarida Damasceno

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer

Cancer Management and Research ◽

10.2147/cmar.s186658 ◽

2019 ◽

Vol Volume 11 ◽

pp. 513-524 ◽

Cited By ~ 2

Author(s):

Reshma L. Mahtani ◽

Charles L. Vogel

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Cyclin Dependent Kinases ◽

Epidermal Growth ◽

702 PUBLICATION Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80997-8 ◽

2005 ◽

Vol 3 (2) ◽

pp. 199

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3512 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3512-3512 ◽

Cited By ~ 4

Author(s):

J. M. Tabernero ◽

E. Van Cutsem ◽

J. Sastre ◽

A. Cervantes ◽

J.-L. Van Laethem ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3535 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3535-3535 ◽

Cited By ~ 42

Author(s):

E. Díaz Rubio ◽

J. Tabernero ◽

E. van Cutsem ◽

A. Cervantes ◽

T. André ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation

Journal of Cancer Research and Therapeutics ◽

10.4103/0973-1482.145851 ◽

2014 ◽

Vol 10 (7) ◽

pp. 155 ◽

Cited By ~ 4

Author(s):

Fang Li ◽

Nan Du ◽

Xiao Zhao ◽

Guangqin Zhu ◽

Huoming Chen ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Brain Metastasis ◽

Lung Adenocarcinoma ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

Oncology ◽

10.1159/000453336 ◽

2017 ◽

Vol 92 (4) ◽

pp. 205-212 ◽

Cited By ~ 2

Author(s):

Hiroko Hasegawa ◽

Hiroya Taniguchi ◽

Seiichiro Mitani ◽

Toshiki Masuishi ◽

Azusa Komori ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Epidermal Growth ◽

Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study

Annals of Oncology ◽

10.1093/annonc/mdx424 ◽

2017 ◽

Vol 28 ◽

pp. vi25

Author(s):

A. D' Alonzo ◽

C. Bighin ◽

F. Puglisi ◽

L. Gerratana ◽

M. De Laurentis ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

Annals of Oncology ◽

10.1093/annonc/mdj084 ◽

2006 ◽

Vol 17 (3) ◽

pp. 450-456 ◽

Cited By ~ 171

Author(s):

G. Folprecht ◽

M.P. Lutz ◽

P. Schöffski ◽

T. Seufferlein ◽

A. Nolting ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Colorectal Carcinoma ◽

Growth Factor Receptor ◽

Line Treatment ◽

Metastatic Colorectal Carcinoma ◽

First Line ◽

Epidermal Growth ◽

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3512 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3512-3512 ◽

Cited By ~ 24

Author(s):

J. M. Tabernero ◽

E. Van Cutsem ◽

J. Sastre ◽

A. Cervantes ◽

J.-L. Van Laethem ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽